Ths TR 0 1 0 0 1 0 2 0 0 NTR 0 0 0 0 0 1 1 0-5.9 dayqwk ?3 biwk ?-7.9 day-9.8 dayqd ?ne ns ns-4.3 day-5.2 Dayqwk ?3 qd ?-15.3 day 14 -5.1 day 42 -0.8 dayThe therapies used included DNA synthesis inhibitors (5-FU, gemcitabine), a DNA alkylating agent (oxaliplatin), a DNA intercalating agent (liposomal doxorubicin), a topoisomerase inhibitor (irinotecan), an EGFR inhibitor (erlotinib), a c-kit inhibitor (imatinib) and an angiogenesis inhibitor (bevacizumab). Therapies were delivered as indicated and tumor growth was continually observed after treatment regimen ceased in order to determine time-to-endpoint (TTE) and difference between median TTE of treated groups vs. placebo (T-C). Statistical significance was evaluated by logrank test, df = 1 with significance indicated by * and non-significance (ns) or not evaluable (ne). Body weight (BW) nadir was shown as percent change and deaths were divided into treatment-related deaths (TR) and non-treatment related deaths (NTR). The final sample size (n) was calculated by removing NTR deaths n number of animals in a group not dead from accidental or unknown causes, or euthanized for sampling, TTE time to endpoint, T-C difference between median TTE (days) of treated group versus control group, TR treatment-related death, NTR non-treatment-related death, Mean BW Nadir lowest group mean body weight, as change from day 1, ne not evaluable, ns not significant Statistical significance (Logrank test, df = 1): * P Nelfinavir (Mesylate) shown to be sparsely expressed around the borders of normal acinar cells and ducts [34, 35]. The Collagen I staining resembles the expression pattern of normal tissue in certain areas (Additional file 2: Figure S1).Gene analysis together with immunofluorescence (IF) and IHC indicates that the PACC patient and PA-018 PDTX model have a BRCA2 mutationFig. 3 Evaluation of serum lipase enzyme levels. a Correlation plot of individual serum lipase levels compared to tumor volume indicated positive correlation with R2 = 0.6949 at day 15 when all groups were actively receiving chemotherapeutics. b Serum analysis for lipase secretion was performed on blood collected at predose, and day 15. Data was plotted as mean ?standard deviation, n = 5. Asterisk indicated P PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/7500280 = 0.079). Of the eight monotherapies, only 5-FU and imatinib were unable to decrease serum.